Search

Displaying results 7611 - 7620 of 10000 in total
  1. Drug

    Luxdegalutamide

    go.drugbank.com/drugs/DB22370
    Investigational

    JSB462 is under investigation in clinical trial NCT07047118 (A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer

  2. Drug

    Izalontamab brengitecan

    go.drugbank.com/drugs/DB22567
    Investigational

    Izalontamab brengitecan is under investigation in clinical trial NCT07054567 (A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial

  3. Drug

    ATORM-C

    go.drugbank.com/drugs/DB33983
    Experimental

    ATORM-C is under investigation in clinical trial NCT07822087 (A Phase 1 Study of ATORM-C in Patients With Crohn's Disease).

  4. Drug

    Valerian

    go.drugbank.com/drugs/DB13196
    Approved

    Valerian has been used in the treatment of conditions including sleep disorders, anxiety, attention deficit-hyperactivity disorder (ADHD) and joint pain.

    Mixtures: VALERIANA E LUPPOLO DISPERT, VALERIANA E LUPPOLO DISPERT
  5. Drug

    Dofequidar

    go.drugbank.com/drugs/DB14067
    Investigational

    Dofequidar is an antineoplastic agent.

  6. Drug

    Cambritaxestat

    go.drugbank.com/drugs/DB18723
    Investigational

    Cambritaxestat is an autotaxin inhibitor.

  7. Drug

    Excindogen

    go.drugbank.com/drugs/DB18754
    Experimental

    Excindogen is an investigational immunotherapy.

  8. Drug

    Pirodavir

    go.drugbank.com/drugs/DB08012
    Experimental

    Pirodavir is an antipicornavirus agent.

  9. Drug

    Levophencynonate

    go.drugbank.com/drugs/DB16011
    Investigational

    Levophencynonate is under investigation in clinical trial NCT02299804 (A Clinical Trial to Evaluate Efficacy and Safety of Levophencynonate Hydrochloride in Patient With Vertigo).

  10. Drug

    EPI-589

    go.drugbank.com/drugs/DB16041
    Investigational

    EPI-589 is under investigation in clinical trial NCT02460679 (Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)).